Lexaria Bioscience Corp LEXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
-
Lexaria Updates Financial Position
-
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
-
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
-
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Lexaria Receives USD$2.6 Million Tax Rebate Payment
-
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
-
Lexaria Enters a Material Transfer Agreement With PegBio
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.11M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
Valuation
|
Metric
|
LEXX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.16 |
Price/Sales | 25.73 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LEXX
|
|---|---|
Quick Ratio | 9.56 |
Current Ratio | 10.60 |
Interest Coverage | — |
Quick Ratio
LEXX
Profitability
|
Metric
|
LEXX
|
|---|---|
Return on Assets (Normalized) | −126.22% |
Return on Equity (Normalized) | −143.73% |
Return on Invested Capital (Normalized) | −152.70% |
Return on Assets
LEXX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|j%%PDY | LOCK|p@&@ | $129B | |||
| Moderna Inc
MRNA
| LOCK|?xBc&m | LOCK|zD | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$vxGQkN | LOCK|rsYr | $77B | |||
| argenx SE ADR
ARGX
| LOCK|W%%N$p | LOCK|Gj | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<&lJC#Q | LOCK|Q$> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|dv<W#Q$ | LOCK|V%J%W | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KMj!!#cY | LOCK|S&^gg | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Dp?%lkk | LOCK|S^< | $24B | |||
| Incyte Corp
INCY
| LOCK|$nT>&R | LOCK|h$& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@<nwLT | LOCK|@VF | $14B |
United States